with a all of ng the insight on the latest deal between gilliard. there, "street smart" is up next. ♪ >> welcome, everyone. to the big show. 60 minutes left to the close. stocks are climbing adding to a three-day rally. the s&p heading to a record high investors bet on low interest rates through the first quarter. walking through the closing bell with tony dwier, managing director. nd how they should be responding to the sony hack attack. i'll speak with the homeland ridge.ty secretary tom "street smart" starts now. the stories. orth korea is off line today according to the monitoring

sharing the news of gilliard down sharply down $11. abbvie up almost $3.illion market cap. >> and down $10 on -- >> $16 billion right there. >> our meg tirrell is here with a special guest. >> let's bring in steve miller. thank you very joining us. >> thanks for having me. >> so let's get right into it. we know that abbvie's drug has an $83,000 list price that the company told us about on friday giving you. >> we never disclose drug prices but you can say, it's a significant discount, big enough to allow us to recommend treating all patients with geno type one hep c. >> folks argue abbvie's regimen has more spills, some need to take it longer than gilead's renlment what happen do you say to doctor whose need the choice to prescribe gilead's drug. >> in the clinical trials the outcomes from the drugs, which never faced head-to-head trials, but the studies demonstrate the outcomes are outstanding. with both drugs cure rates over 90%. abbvie's done a phenomenal job of packaging the product, convenient to take. comes in a blister pack with morning dose, your e